Much more comprehensive and easy to understand than this study's entry on ClinicalTrials.
Study Methodology
In this study, the Mansoura University investigators and study team seek to compare the rate of time of viral clearance in subjects receiving the combination of Nitazoxanide, Ribavirin and Ivermectin versus a control group (without intervention). Documented in their disclosure to Clinicaltrials.gov, the study team opted to design a “sequential clinical trial,” meaning the sample size is not fixed in advanced. Rather, the team actually evaluates data as it gets collected, and additional sampling is halted based on a pre-defined rule as soon as soon as significant results are observed. For example, after each group of “n” (10 subjects in each group) subjects in each group are available, the team will conduct an interim analysis proceeded by statistical tests comparing the two groups; if the null hypothesis is rejected, the trial is terminated. Otherwise, the trial continues and another “n” subjects per group would be recruited and the statistical tests performed all over again, including all subjects. If the null is rejected, again the trial would be terminated or else it continues with periodic evaluations until a maximum number of interim analyses have been performed, at which point the last statistical test is conducted and the trial would then be discontinued.
it commenced this month and runs through May 2022 (study first posted May 18, 2020); however, as mentioned, based on its design and methodology, it could end much earlier.
[-] TrumpLyftAlles | 1 points | May 22 2020 23:06:35
Much more comprehensive and easy to understand than this study's entry on ClinicalTrials.
Study Methodology
In this study, the Mansoura University investigators and study team seek to compare the rate of time of viral clearance in subjects receiving the combination of Nitazoxanide, Ribavirin and Ivermectin versus a control group (without intervention). Documented in their disclosure to Clinicaltrials.gov, the study team opted to design a “sequential clinical trial,” meaning the sample size is not fixed in advanced. Rather, the team actually evaluates data as it gets collected, and additional sampling is halted based on a pre-defined rule as soon as soon as significant results are observed. For example, after each group of “n” (10 subjects in each group) subjects in each group are available, the team will conduct an interim analysis proceeded by statistical tests comparing the two groups; if the null hypothesis is rejected, the trial is terminated. Otherwise, the trial continues and another “n” subjects per group would be recruited and the statistical tests performed all over again, including all subjects. If the null is rejected, again the trial would be terminated or else it continues with periodic evaluations until a maximum number of interim analyses have been performed, at which point the last statistical test is conducted and the trial would then be discontinued.
it commenced this month and runs through May 2022 (study first posted May 18, 2020); however, as mentioned, based on its design and methodology, it could end much earlier.
permalink